Back to today’s briefing

Story perspectives

IVIG Cuts Severe Infections in Myeloma Patients by 73%

1/10/2025

24 4

Summary

Story summary

A groundbreaking study reveals that intravenous immunoglobulin (IVIG) dramatically lowers the risk of severe infections in multiple myeloma patients treated with teclistamab. Among 168 participants, only 9.8% on IVIG experienced serious infections, a stark contrast to 38% without it. This underscores the importance of tailored therapies to enhance patient safety and outcomes.

1 of 1

Story summary

A groundbreaking study reveals that intravenous immunoglobulin (IVIG) dramatically lowers the risk of severe infections in multiple myeloma patients treated with teclistamab. Among 168 participants, only 9.8% on IVIG experienced serious infections, a stark contrast to 38% without it. This underscores the importance of tailored therapies to enhance patient safety and outcomes.